Stoke Therapeutics, Inc. (NASDAQ: STOK) reported Q4 EPS of ($0.18), $0.37 better than the analyst estimate of ($0.55). Revenue for the quarter came in at $22.61 million versus the consensus estimate of $4.1 million.

For earnings history and earnings-related data on Stoke Therapeutics, Inc. (STOK) click here.